With the pandemic continuing its deadly spread, individual countries are taking steps to address the growing number of COVID-related drug shortages, and regulator-industry cooperation is the order of the day. The increased risk of fake and unlicensed medical products has been highlighted, as have concerns about the data protection aspects of using technology to understand the spread of the coronavirus.
Supplies of vital medicines used for treating hospitalized COVID-19 patients are beginning to run dry in some EU member states. Particularly hard hit are anesthetics, antibiotics and muscle relaxants used in intensive care units, as well as medicines used off-label or in clinical trials for treating the coronavirus. France, for example, recently said it was allowing the import of propofol and has even given the go-ahead for veterinary versions of the anesthetic to be used in humans
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?